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Abstract
Purpose Haemangioma of infancy (HOI) is the most
frequently occurring benign tumour of infancy. Alarming
HOI require treatment. Current therapy is empirically
based; corticosteroids are often administered but in recent
publications propranolol was reported to be more effective.
Peri-ocular HOI are highly sensitive to corticosteroids. Our
goal was to evaluate the effectiveness of intra-lesional
corticosteroids in the treatment of peri-ocular HOI.
Methods We selected all patients with peri-ocular HOI
who had only been treated with intra-lesional
corticosteroids at our hospital from 1993 until 2009.
Treatment was standardized according to a prospective
protocol.
Results A total of n = 34 patients were included. There
were no complications at all after therapy. A second intra-
lesional injection was necessary in five patients. At follow-
up after 6 and 12 months after injection, 94 and 91% of the
patients, respectively, had regression of the HOI. Astig-
matism, Haemangioma Activity Score and global assess-
ments all had improved after therapy.
Conclusions This study shows that intra-lesional therapy
with corticosteroids is very safe in the treatment of peri-
ocular HOI. It remains a good and safe alternative besides
propranolol or when propranolol therapy is not possible (e.g.
asthma, PHACE syndrome, and certain cardiac diseases).
Keywords Haemangioma  Intra-lesional
corticosteroids  Propranolol  Therapy
Introduction
Haemangioma of infancy (HOI) [1] is the most common,
benign, self-limiting tumour of infancy [2, 3] and therefore
needs no treatment [4]. It is commonly located on the face
[5]. However, HOI may cause severe complications [4],
generally because of extensive growth or location, leading
to (besides psychological problems) life-threatening or
disabling complications [6] (e.g. compression of the air-
ways, heart failure, ulceration and visual problems).
Amblyopia or reduced vision in the affected eye, secondary
to astigmatism or visual deprivation affects 43–60% of the
children with peri-ocular HOI [1]. Of course, such HOI
require treatment. However, the current therapy in HOI is
empirically based. Systemic or intra-lesional corticosteroid
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treatment is often administered [7]. Peri-ocular HOI are
particularly sensitive to corticosteroids. In recent publica-
tions, propranolol [8, 9] was reported to be either more or
at least equally effective in treating proliferative HOI.
Other alternatives among others are [10] laser therapy,
intravenous vincristine, cyclophosphamide and recombi-
nant interferon alfa [11] (high risk for adverse events),
local/intra-lesional imiquimod, becaplermin (recombinant
platelet-derived growth factor) and bleomycin. Apart from
waiting for involution or surgical resection, treatment aims
at inducing or accelerating the natural involution process
[12]. Although there is extensive literature, objective
measures of astigmatism and anisometropia before and
after treatment are limited. In this article we evaluate the
effectiveness of intra-lesional corticosteroids in the treat-
ment of peri-ocular HOI.
Methods
Study design and patient selection
In 1993 Oranje, de Laat and Madern started a special
outpatient clinic called workgroup on vascular abnormali-
ties Rotterdam (WEVAR) at our hospital, for children with
threatening, very large, or fast-growing vascular abnor-
malities. This outward clinic is multi-disciplinary and
includes as a basic team paediatric dermatologist (APO),
paediatrician (PCJL) and paediatric surgeon (GCM). Other
specialists are consulted if necessary. Treatment (when
necessary) is standardized. One of the therapy options is
intra-lesional corticosteroids (a mixture of 2 ml kenacort-A
40 mg/ml and 3 ml celestone 4 mg/ml), and these are
administered at a dose of 1–5 ml at one or multiple sites,
depending on the size of the lesion. Corticosteroids are
injected with a 23G 1 in. needle. During the procedure, the
paediatric surgeon (visually) checks the site of injection.
The position of the needle is checked both visually and by
palpation. Injection in a great vessel is prevented by
checking for blood return in the needle (aspirate). After the
procedure, pressure on the injection site(s) with gauze and
using the fingers was performed by the paediatric surgeon
until haemostasis had been reached. Standard controls after
the procedure consist of checking the site of injection, the
eye, general condition, and, by indication, hormonal con-
trols or eye examinations by an ophthalmologist. Fig-
ure 1a–c show the course of a peri-ocular HOI, treated with
intra-lesional corticosteroids.
Patients with alarming (threatening) peri-ocular HOI
who needed treatment, e.g. because they were (at risk of)
developing amblyopia, were treated according to a WE-
VAR protocol including ultrasonography of the peri-ocular
region and eye examinations prior to therapy. These eye
examinations (cycloplegic refractions of both eyes) were
also protocolized and performed by a paediatric ophthal-
mologist. Patients received one drop of a solution con-
taining 2.5% phenylephrine and 0.5% tropicamide in each
eye. After 15–20 min this was repeated. The examination
started 15–20 min after the second drops were adminis-
tered to the patients. Spherical and cylindrical abnormali-
ties were assessed using skiascopy. All patients were
awake during the eye examinations.
Inclusion and exclusion criteria
All of the patients with alarming peri-ocular HOI (i.e. the
eye was at risk because of such threatening HOI) who were
treated with intra-lesional corticosteroids from 1993 until
2009 were included in this study. Patients who were treated
with both systemic and intra-lesional corticosteroids were
excluded, as were patients with HOI at another location
than peri-ocular. Patients with intra-orbital HOI are not
treated with intra-lesional therapy. Data was obtained by
investigating the patients’ medical dossiers. Photographs
that had been taken were assessed.
Scoring HOI
The effect of treatment was evaluated by the Haemangioma
Activity Score (HAS) [13]. This scoring system focuses on
Fig. 1 a A peri-ocular haemangioma of infancy (HOI) in an almost
six months old girl at t = 0. Note the swelling which closes the eye.
b Six months after treatment with intra-lesional corticosteroids: the
HOI is in regression and the eye can be opened again. c 12 months
after treatment with intra-lesional corticosteroids: the HOI is almost
gone
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the (disease) proliferative activity of a HOI at a certain
time point. Scores at multiple time points of one HOI in
one patient can be compared with each other.
Outcome measures
HAS before and after treatment was calculated at t = 0, 6
and 12 months from the photographs. We searched all
patients’ medical dossiers for complications. The global
assessments at the check-ups on the size of the HOI were
collected as were the ophthalmic measurements made by
the ophthalmologist.
Statistical methods
SPSS version 15.0.0 was used for the database and statis-
tical measures. Differences in astigmatism, in matters of
refractive cylindrical value, and HAS between the three
time points were assessed using Friedman’s test.
Results
In the period 1993–2009 a total of n = 67 patients with
HOI were treated with intra-lesional corticosteroids. After
excluding patients with concomitant HOI other than peri-
ocular HOI (n = 28) and patients who had both systemic
and intra-lesional therapy (n = 5), a total of n = 34
patients were included. These patients were treated with
only intra-lesional corticosteroids because of an alarming
peri-ocular HOI. Their baseline characteristics are shown
in Table 1. 88% of patients were females and 82% full
term (gestational age [37 weeks). 9% of patients were
twins. The mean age at which the HOI started to develop
was 0.63 months (SD 0.67 months). The number of HOI in
Table 1 Demographics and
baseline characteristics of
n = 34 patients with peri-ocular
HOI treated only with intra-
lesional therapy
a Five patients with a
gestational age between 33 and
35 weeks, one patient with a
gestational age of 25 3/7 weeks
Characteristic Rx/intra-lesional corticosteroids (n = 34)
Sex (%) Female: 88
Male: 12
Gestational age (%) [37 weeks: 82
Premature: 18a
Gemini (%) No: 91
Yes: 9
Median age of development of HOI 0.4 months (10th percentile = 0.0; 90th
percentile = 1.75)
Median number of HOI per patient 1 (10th percentile = 1; 90th percentile = 4)
Size of HOI (assessed by ultrasonography)
(%)
\3 cm: 71
3–10 cm: 26
[10 cm: 3
Median age at start intra-lesional therapy 3.8 months (10th percentile = 2; 90th percentile = 9)
Table 2 Outcomes of intra-
lesional corticosteroid therapy
in n = 34 patients with
alarming peri-ocular
haemangioma of infancy (HOI)
at t = 0 (baseline, just before
intra-lesional therapy), 6 and 12
(6 and 12 months after
injection)
* p \ 0.001
** p = 0.011
t = 0 t = 6 months t = 12 months
Mean HAS 3.0 (SD 1.3) 2.1 (SD 0.9) 1.6 (SD 0.7)*
Refraction: mean astigmatism (diopters) 2.57 (SD 1.49) 1.84 (SD 1.01) 1.44 (SD 1.26)**
Occlusion therapy (for amblyopia) (%)
Yes 46 40 28
No 54 60 72
Therapy effect (evaluation by the doctor) (%)
Smaller 94 91
Same 6 6
Worse 0 3
Complications (%)
Yes 0 0
No 100 100
Plastic surgery required until 2009? (%)
Yes 9
No 81
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each patient ranged from 1 to 5 but most patients had 1
HOI (median number = 1, 10th percentile = 1, 90th per-
centile = 4) and most HOI were small (71% \ 3 cm,
3% [ 10 cm, greatest diameter taken on ultrasonography).
Finally, the median age of first intra-lesional therapy was
3.8 months (10th percentile = 2, 90th percentile = 9).
Of these n = 34 patients, 5 patients were given a second
intra-lesional corticosteroid injection. Table 2 shows the
outcomes of the therapy at 6 and 12 months after the first
injection. HAS declined from 3 (SD 1.3) at baseline to 2.1
(SD 0.9) after 6 months and 1.6 (SD 0.7) after 12 months
after the first injection (p = 0.000). Global scores by the
doctor strengthen the (reduction in) HAS: after 6 months
94% was scored as ‘smaller’, after 12 months this was 91%
(6% was the same and 3% worse). Astigmatism shows a
similar trend as the HAS: mean cylindrical diopters drop-
ped from 2.57 (SD 1.49) at baseline to 1.84 (SD 1.01) after
6 months and 1.44 (SD 1.26) after 12 months (p = 0.011).
At baseline, 46% of the patients had occlusion therapy,
after 6 months 40% and after 12 months only 28% of all
patients still had occlusion therapy. Until now, 9% of
patients had plastic surgery. Most importantly we did not
see any (lasting) complications. In one patient we did see
peri-ocular calcification, but this appeared to be reversible.
Discussion
This study showed that intra-lesional therapy with corti-
costeroids is a very safe alternative in the treatment of
(peri-ocular) HOI as no complications were observed by
us. HAS, eye examinations, and clinical appearance all
improved after intra-lesional therapy. Since HOI is a self-
limiting tumour, the expectation is that HAS and clinical
appearance would eventually improve, but we were able to
demonstrate that when an eye is at risk of visual impair-
ment, intra-lesional therapy is highly effective: all eye
examinations (especially cylindrical abnormalities)
improved after treatment.
In 9% of our cases, plastic surgery was indicated in a
later stage. However, this did not mean that intra-lesional
therapy was not effective. The HOI did regress faster. We
think that without the intra-lesional therapy or with another
therapy, a scar would have eventually developed that
required plastic surgery. It is possible that this percentage
may have been higher because some patients could have
gone to another hospital or may require plastic surgery in
the future.
Our results of the treatment with intra-lesional cortico-
steroids for peri-ocular HOI are excellent with a success
rate of 85% after one injection and 100% after two injec-
tions, without any adverse events. These percentages are
somewhat higher than those reported in the literature. 50%
of HOI respond after therapy with corticosteroids, peri-
ocular HOI are more sensitive, with rates up to 64% [10,
14, 15]. These differences are probably attributed to other
measures of effect and success. Often, the amount of cor-
ticosteroids that were administered in those cases is also
difficult to establish. We treated all patients in a stan-
dardized manner.
The possible side effects are as follows: injection pres-
sure during intra-lesional injection usually exceeds sys-
temic arterial pressure and poses a risk of corticosteroid
particle embolization into the ocular circulation due to
retrograde arterial flow. Serious ocular complications
include ophthalmic artery occlusion, retinal embolization
and central retinal artery occlusion. Others are eyelid hypo-
pigmentation, linear subcutaneous fat atrophy, scleroder-
miform linear atrophy, eyelid necrosis and peri-ocular
calcification. Rare systemic side effects include cushingoid
features, growth deceleration and adrenal suppression [10,
15]. We did not encounter any of these side effects. Peri-
ocular calcification was seen in one patient but appeared to
be reversible (see Fig. 2a–c). The most important thing is
to aspirate for blood after injection and inject with care. For
example, if the HOI is located in the eyeball, intra-lesional
therapy is dangerous because the HOI expands while cor-
ticosteroids are administered leading to compromised per-
fusion and visual loss. An extension of the HOI into the
orbital cavity can also be associated with complications,
and therefore we do not treat such patients with intra-le-
sional therapy.
Fig. 2 a A peri-ocular haemangioma of infancy (HOI) in a four
months old boy at t = 0. b Six months after intra-lesional
corticosteroids: the HOI is in regression. Note the peri-ocular
calcification. c Two years after intra-lesional corticosteroids: the
peri-ocular calcification appeared to be reversible
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Furthermore, female to male ratio is slightly high in our
study, but agrees with the reported findings that HOI is
more common in girls [12]. We also observed that most
patients had a small (\3 cm) HOI.
In spite of these good results, intra-lesional therapy of
HOI with corticosteroids is undergoing a transformation.
Today there is an increasing interest on propranolol in the
treatment of HOI with promising results and until now few
reported side effects. We think that it has almost become
the first choice of treatment. The results of this study
showed that intra-lesional injection with corticosteroids is
still a safe alternative for treating (peri-ocular) HOI when
propranolol is not effective or when propranolol is (rela-
tively) contra-indicated (e.g. asthma, certain cardiac dis-
eases, multiple medication causing extra burden and
PHACE syndrome [16]). The recent study reported by
Greenberger et al. [17] elucidated the effect of corticoste-
roids on angiogenesis and vasculogenesis. Certain advan-
tages and disadvantages of both propranolol and intra-
lesional therapy are summarized in Table 3. We conclude
that intra-lesional therapy with corticosteroids still has a
valuable place in the treatment of HOI.
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